Literature DB >> 23860513

[Recommendations for the treatment of heart failure : What's new?].

G Hasenfuß1, F Edelmann, R Wachter.   

Abstract

Treatment escalation of chronic systolic heart failure depends on left ventricular function and symptoms of the patients. In symptomatic patients with severely reduced left ventricular function (ejection fraction ≤ 30 %), the following therapeutic approaches are recommended: (1) angiotensin-converting enzyme (ACE) inhibitors (angiotensin receptor blocker in case of ACE inhibitor intolerance); (2) β-blockers; (3) mineralocorticoid receptor antagonists; (4) diuretics in case of signs and symptoms of congestion; (5) digitalis, in particular in patients with atrial fibrillation; (6) ivabradine in patients with sinus rhythm and a heart rate ≥ 75/min; (7) an implantable cardioverter defibrillator (ICD); (8) in case of left bundle branch block or wide QRS complex, cardiac resynchronization therapy (CRT; in most cases in combination with an implantable cardioverter defibrillator); (9) intravenous administration of iron in case of iron deficiency; (10) exercise training should be strongly recommended in patients with stable heart failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860513     DOI: 10.1007/s00108-013-3312-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  Cardiac-resynchronization therapy for mild-to-moderate heart failure.

Authors:  Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Rehospitalization for heart failure: predict or prevent?

Authors:  Akshay S Desai; Lynne W Stevenson
Journal:  Circulation       Date:  2012-07-24       Impact factor: 29.690

4.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Authors:  John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

5.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

6.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

7.  Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction.

Authors:  Todd M Koelling; Keith D Aaronson; Robert J Cody; David S Bach; William F Armstrong
Journal:  Am Heart J       Date:  2002-09       Impact factor: 4.749

8.  Treatment of anemia with darbepoetin alfa in systolic heart failure.

Authors:  Karl Swedberg; James B Young; Inder S Anand; Sunfa Cheng; Akshay S Desai; Rafael Diaz; Aldo P Maggioni; John J V McMurray; Christopher O'Connor; Marc A Pfeffer; Scott D Solomon; Yan Sun; Michal Tendera; Dirk J van Veldhuisen
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

10.  Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Authors:  Jean-Claude Tardif; Eileen O'Meara; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Luigi Tavazzi; Karl Swedberg
Journal:  Eur Heart J       Date:  2011-08-29       Impact factor: 29.983

View more
  2 in total

1.  [Heart failure. A medical challenge].

Authors:  G Hasenfuß
Journal:  Internist (Berl)       Date:  2014-06       Impact factor: 0.743

2.  Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with asymptomatic chronic heart failure.

Authors:  Yuan Zhang; Yanming Li; Guanchang Cheng
Journal:  Exp Ther Med       Date:  2015-10-30       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.